JP2008539241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539241A5 JP2008539241A5 JP2008508984A JP2008508984A JP2008539241A5 JP 2008539241 A5 JP2008539241 A5 JP 2008539241A5 JP 2008508984 A JP2008508984 A JP 2008508984A JP 2008508984 A JP2008508984 A JP 2008508984A JP 2008539241 A5 JP2008539241 A5 JP 2008539241A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- amino acid
- pta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 36
- 102000036639 antigens Human genes 0.000 claims 36
- 108091007433 antigens Proteins 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 28
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 16
- 108010056852 Myostatin Proteins 0.000 claims 16
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 13
- 102220045254 rs374739820 Human genes 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 3
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 2
- 101710176384 Peptide 1 Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- -1 i.e. Proteins 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000003270 steroid hormone Substances 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 108010059616 Activins Proteins 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 1
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000000488 activin Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000014101 glucose homeostasis Effects 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 230000037257 muscle growth Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000036963 noncompetitive effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67493305P | 2005-04-25 | 2005-04-25 | |
| PCT/US2006/015407 WO2006116269A2 (en) | 2005-04-25 | 2006-04-24 | Antibodies to myostatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008539241A JP2008539241A (ja) | 2008-11-13 |
| JP2008539241A5 true JP2008539241A5 (OSRAM) | 2009-04-30 |
Family
ID=37215358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508984A Pending JP2008539241A (ja) | 2005-04-25 | 2006-04-24 | ミオスタチンに対する抗体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7807159B2 (OSRAM) |
| EP (2) | EP2295466A3 (OSRAM) |
| JP (1) | JP2008539241A (OSRAM) |
| KR (1) | KR20080011403A (OSRAM) |
| CN (1) | CN101272802A (OSRAM) |
| AP (1) | AP2007004243A0 (OSRAM) |
| AR (1) | AR053067A1 (OSRAM) |
| AU (1) | AU2006239860B2 (OSRAM) |
| BR (1) | BRPI0610248A2 (OSRAM) |
| CA (1) | CA2605723A1 (OSRAM) |
| CR (1) | CR9466A (OSRAM) |
| DO (1) | DOP2006000093A (OSRAM) |
| EA (2) | EA201100642A1 (OSRAM) |
| IL (1) | IL186739A (OSRAM) |
| MA (1) | MA29524B1 (OSRAM) |
| MX (1) | MX2007013217A (OSRAM) |
| NL (3) | NL1031674C2 (OSRAM) |
| NO (1) | NO20076061L (OSRAM) |
| PE (1) | PE20061395A1 (OSRAM) |
| TN (1) | TNSN07394A1 (OSRAM) |
| TW (1) | TW200724548A (OSRAM) |
| WO (1) | WO2006116269A2 (OSRAM) |
| ZA (1) | ZA200709291B (OSRAM) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2852549T3 (es) | 2005-02-09 | 2021-09-13 | Sarepta Therapeutics Inc | Composición antisentido para tratamiento de la atrofia muscular |
| WO2007044411A2 (en) * | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| MX2008006626A (es) | 2005-11-23 | 2008-09-24 | Acceleron Pharma Inc | Antagonistas de activin-actriia y usos para promover el crecimiento de huesos. |
| WO2007076062A2 (en) * | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| HRP20130320T1 (en) * | 2006-09-05 | 2013-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
| AU2012265564B2 (en) * | 2006-09-08 | 2016-05-26 | Amgen Inc | Anti-activin A antibodies and uses thereof |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| CA2868899C (en) | 2007-06-01 | 2017-06-13 | Wyeth Llc | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| PL2170396T3 (pl) | 2007-08-03 | 2017-07-31 | Summit (Oxford) Limited | Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| EP2245064B1 (en) * | 2007-12-21 | 2014-07-23 | Medimmune Limited | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha) |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| EP2899209A1 (en) | 2008-04-29 | 2015-07-29 | Abbvie Inc. | Dual Variable Domain Immunoglobulins and uses thereof |
| BRPI0913406A2 (pt) | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
| EP2297208A4 (en) | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| CA2735900A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
| WO2010080463A1 (en) * | 2008-12-18 | 2010-07-15 | Imclone Llc | Antibody humanization |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| TW201613969A (en) | 2009-03-05 | 2016-04-16 | Abbvie Inc | IL-17 binding proteins |
| US8716450B2 (en) | 2009-10-15 | 2014-05-06 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US8841417B2 (en) | 2010-05-14 | 2014-09-23 | Abbvie Inc. | IL-1 binding proteins |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| UY33421A (es) * | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| SG10201506405YA (en) * | 2010-08-16 | 2015-10-29 | Amgen Inc | Polypeptides That Bind Myostatin, Compositions And Methods |
| PE20140229A1 (es) | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| US10920242B2 (en) | 2011-02-25 | 2021-02-16 | Recombinetics, Inc. | Non-meiotic allele introgression |
| US9528124B2 (en) | 2013-08-27 | 2016-12-27 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| WO2013074557A1 (en) | 2011-11-14 | 2013-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
| TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 |
| KR101704893B1 (ko) * | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
| ES2791778T3 (es) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4 |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| PL2887959T3 (pl) * | 2012-08-23 | 2019-04-30 | Agensys Inc | Koniugaty leków i przeciwciał (adc), które wiążą białka 158p1d7 |
| WO2014030728A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | FcγRIIb特異的Fc領域改変体 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| PL3564258T3 (pl) | 2012-09-13 | 2021-10-25 | Bristol-Myers Squibb Company | Oparte na fibronektynie białka z domeną rusztowania, które wiążą się z miostatyną |
| UY35110A (es) | 2012-11-01 | 2014-05-30 | Abbvie Inc | Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP3985024A1 (en) | 2013-02-01 | 2022-04-20 | Atara Biotherapeutics, Inc. | Anti-activin-a compounds for the treatment of ovarian cancer |
| CN103145836A (zh) * | 2013-02-07 | 2013-06-12 | 浙江大学 | 抗肌抑素单链抗体及其编码基因、表达载体、重组转化子和应用 |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| CA2904448A1 (en) | 2013-03-15 | 2014-09-18 | Tariq Ghayur | Dual specific binding proteins directed against il-1.beta. and/or il-17 |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| JP2016518357A (ja) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
| PL2981822T3 (pl) | 2013-05-06 | 2021-07-12 | Scholar Rock, Inc. | Kompozycje i sposoby modulacji czynnika wzrostu |
| EP3007719B1 (en) * | 2013-06-11 | 2021-03-17 | President and Fellows of Harvard College | Methods and compositions for increasing neurogenesis and angiogenesis |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| EP3041863A4 (en) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| JP2017509647A (ja) * | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| TW201622746A (zh) * | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
| CA2949237C (en) | 2014-05-16 | 2022-08-23 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| IL278014B2 (en) | 2014-12-19 | 2023-10-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use |
| SG10201907215QA (en) | 2015-02-05 | 2019-09-27 | Chugai Pharmaceutical Co Ltd | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US10100118B2 (en) | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
| JP2018513856A (ja) * | 2015-04-08 | 2018-05-31 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｃｄ１２３に結合する抗体治療剤 |
| EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| JP6664129B2 (ja) * | 2015-09-10 | 2020-03-13 | 学校法人慶應義塾 | 筋萎縮の予防剤及び／又は治療剤のスクリーニング方法 |
| PL3350220T3 (pl) * | 2015-09-15 | 2022-01-03 | Scholar Rock, Inc. | Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania |
| WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| CA3002422C (en) | 2015-12-18 | 2024-04-16 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| JP6948331B2 (ja) | 2016-01-06 | 2021-10-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Ｇｄｆ１１での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する |
| AU2017206069A1 (en) | 2016-01-08 | 2018-07-19 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
| RU2613420C1 (ru) * | 2016-04-13 | 2017-03-16 | Сергей Михайлович Юдин | Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата |
| PT3368069T (pt) | 2016-06-13 | 2020-11-11 | Scholar Rock Inc | Uso de inibidores da miostatina e terapias de combinação |
| KR102376582B1 (ko) | 2016-06-17 | 2022-03-18 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체 및 사용 방법 |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| LT3555132T (lt) * | 2016-12-19 | 2024-02-26 | Medimmune Limited | Antikūnai prieš lif ir jų panaudojimas |
| SI3565592T1 (sl) * | 2017-01-06 | 2023-05-31 | Scholar Rock, Inc. | Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina |
| CA3056011A1 (en) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| IL321873A (en) | 2018-03-01 | 2025-08-01 | Regeneron Pharma | Methods for altering body composition |
| CN111954719B (zh) | 2018-03-26 | 2025-07-18 | 美国安进公司 | 细胞培养物中产生的抗体的总去岩藻糖基化糖型 |
| SI3773713T1 (sl) | 2018-04-06 | 2025-08-29 | Regeneron Pharmaceuticals, Inc. | Protitelo, agonist leptinskega receptorja, za uporabo pri povečanju kostne mase pri osebi, ki trpi zaradi presnovne disfunkcije ali hipoleptinemije |
| CA3123024A1 (en) | 2018-12-18 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
| KR20210117271A (ko) | 2018-12-21 | 2021-09-28 | 노쓰웨스턴유니버시티 | 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용 |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| WO2020183245A2 (en) | 2019-03-11 | 2020-09-17 | Janssen Pharmaceutica Nv | ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES |
| BR112022005583A2 (pt) | 2019-09-26 | 2022-09-20 | Amgen Inc | Métodos para a produção de composições de anticorpos |
| RU2750267C1 (ru) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата |
| CN111500581A (zh) * | 2020-05-26 | 2020-08-07 | 上海海洋大学 | 一种鲢鱼和鳙鱼肌间刺变粗的分子育种方法 |
| CN111560401A (zh) * | 2020-05-26 | 2020-08-21 | 上海海洋大学 | 一种翘嘴红鲌和团头鲂肌间刺变粗的分子育种方法 |
| CN111549031A (zh) * | 2020-05-26 | 2020-08-18 | 上海海洋大学 | 一种草鱼和青鱼肌间刺变粗的分子育种方法 |
| CN111549030A (zh) * | 2020-05-26 | 2020-08-18 | 上海海洋大学 | 一种鲫鱼肌间刺变粗的分子育种方法 |
| EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| TW202227494A (zh) * | 2020-09-11 | 2022-07-16 | 美商健生生物科技公司 | 多特異性免疫靶向分子及其用途 |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| EP4211170A4 (en) | 2020-09-11 | 2024-10-09 | Janssen Biotech, Inc. | METHODS AND COMPOSITIONS FOR MODULATING BETA-CHAIN-MEDIATED IMMUNITY |
| KR20230087539A (ko) | 2020-10-15 | 2023-06-16 | 암젠 인크 | 항체 생산 방법에서의 상대적인 비결합 글리칸 |
| KR20230130639A (ko) * | 2020-12-03 | 2023-09-12 | (주)라트바이오 | 마이오스타틴 유전자가 변형된 형질전환 동물 |
| TW202317614A (zh) | 2021-06-07 | 2023-05-01 | 美商安進公司 | 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平 |
| WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| CN114891101B (zh) * | 2021-12-02 | 2023-06-16 | 吉林省农业科学院 | 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用 |
| EP4499703A2 (en) * | 2022-03-31 | 2025-02-05 | The Wistar Institute of Anatomy and Biology | Antibodies against human siglec-9 and use thereof for immunotherapy |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
| CN115951044B (zh) * | 2022-12-02 | 2025-02-18 | 北京世纪沃德生物科技有限公司 | 基于胶乳免疫比浊法测定s100a8/9的试剂盒及方法 |
| KR20250122524A (ko) | 2022-12-22 | 2025-08-13 | 스칼러 락, 인크. | 미오스타틴 활성화의 선택적이고 강력한 억제 항체 |
| WO2024220916A1 (en) | 2023-04-20 | 2024-10-24 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5151510A (en) * | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU664976B2 (en) * | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
| US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| EP1471142B1 (en) | 1991-04-10 | 2008-11-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| ATE193301T1 (de) * | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| AU705616B2 (en) * | 1995-04-21 | 1999-05-27 | Cell Genesys, Inc. | Generation of large genomic DNA deletions |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| WO1999045031A2 (en) | 1998-03-03 | 1999-09-10 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| DE69934967T2 (de) | 1998-12-08 | 2007-12-06 | Biovation Ltd. | Verfahren zur verminderung der immunogenität von proteinen |
| SG143018A1 (en) | 1998-12-23 | 2008-06-27 | Pfizer | Human monoclonal antibodies to ctla-4 |
| US6517529B1 (en) * | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| EP1461081A4 (en) * | 2001-12-03 | 2006-05-17 | Abgenix Inc | ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION |
| JP2005512044A (ja) | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | 結合特性に基づく抗体分類 |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| CA2508375C (en) * | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| KR20060026860A (ko) | 2003-06-02 | 2006-03-24 | 와이어쓰 | 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도 |
| EP1729793B1 (en) * | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| JP4695133B2 (ja) * | 2004-03-23 | 2011-06-08 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
-
2006
- 2006-04-24 AP AP2007004243A patent/AP2007004243A0/xx unknown
- 2006-04-24 AU AU2006239860A patent/AU2006239860B2/en not_active Expired - Fee Related
- 2006-04-24 US US11/410,886 patent/US7807159B2/en active Active
- 2006-04-24 WO PCT/US2006/015407 patent/WO2006116269A2/en not_active Ceased
- 2006-04-24 EA EA201100642A patent/EA201100642A1/ru unknown
- 2006-04-24 EP EP10179676A patent/EP2295466A3/en not_active Withdrawn
- 2006-04-24 TW TW095114579A patent/TW200724548A/zh unknown
- 2006-04-24 MX MX2007013217A patent/MX2007013217A/es active IP Right Grant
- 2006-04-24 NL NL1031674A patent/NL1031674C2/nl not_active IP Right Cessation
- 2006-04-24 EP EP06751200A patent/EP1877075A4/en not_active Withdrawn
- 2006-04-24 BR BRPI0610248-4A patent/BRPI0610248A2/pt not_active IP Right Cessation
- 2006-04-24 ZA ZA200709291A patent/ZA200709291B/xx unknown
- 2006-04-24 JP JP2008508984A patent/JP2008539241A/ja active Pending
- 2006-04-24 PE PE2006000423A patent/PE20061395A1/es not_active Application Discontinuation
- 2006-04-24 DO DO2006000093A patent/DOP2006000093A/es unknown
- 2006-04-24 KR KR1020077027393A patent/KR20080011403A/ko not_active Ceased
- 2006-04-24 EA EA200702327A patent/EA015534B1/ru not_active IP Right Cessation
- 2006-04-24 AR ARP060101625A patent/AR053067A1/es unknown
- 2006-04-24 CA CA002605723A patent/CA2605723A1/en not_active Abandoned
- 2006-04-24 CN CNA2006800220359A patent/CN101272802A/zh active Pending
-
2007
- 2007-04-05 NL NL1033650A patent/NL1033650C2/nl not_active IP Right Cessation
- 2007-10-18 IL IL186739A patent/IL186739A/en not_active IP Right Cessation
- 2007-10-23 CR CR9466A patent/CR9466A/es not_active Application Discontinuation
- 2007-10-24 TN TNP2007000394A patent/TNSN07394A1/en unknown
- 2007-11-22 MA MA30410A patent/MA29524B1/fr unknown
- 2007-11-26 NO NO20076061A patent/NO20076061L/no not_active Application Discontinuation
-
2008
- 2008-11-25 NL NL2002255A patent/NL2002255C2/nl not_active IP Right Cessation
-
2010
- 2010-08-26 US US12/869,060 patent/US20110091455A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539241A5 (OSRAM) | ||
| US12029788B2 (en) | Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody | |
| KR102440044B1 (ko) | 항-액티빈 a 항체 및 그의 용도 | |
| RU2766094C2 (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
| KR102163001B1 (ko) | 알파-시누클레인을 인식하는 항체 | |
| KR101859911B1 (ko) | 사람 ｇｄｆ８에 대한 항체 | |
| US8992913B2 (en) | Antagonist antibodies against GDF-8 and uses therefor | |
| JP2020536532A5 (OSRAM) | ||
| CN100374465C (zh) | 抗gdf－8的中和抗体及其用途 | |
| JP2017532952A5 (OSRAM) | ||
| JP2019513018A5 (OSRAM) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2010511388A5 (OSRAM) | ||
| JP2018500014A5 (OSRAM) | ||
| BR112013028655B1 (pt) | Anticorpos anti-fator de crescimento neuronal, composição farmacêutica compreendendo os mesmos e kit para o tratamento de dor em felinos | |
| TW201130973A (en) | Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof | |
| JP2008542278A5 (OSRAM) | ||
| JP2003532409A5 (OSRAM) | ||
| EP3661553A2 (en) | Methods and compositions for treatment of amyloid deposition diseases | |
| JP2009502952A5 (OSRAM) | ||
| JP2015518368A5 (OSRAM) | ||
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| IL277899B2 (en) | Methods and preparations for treating yellow fever | |
| WO2024183622A1 (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| JP2010521139A5 (OSRAM) |